First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast Cancer

Abstract

In patients with ER-positive, HER2-negative advanced breast cancer with an <i>ESR1</i> mutation that emerged during treatment, those who were switched to camizestrant with continuation of a CDK4/6 inhibitor during first-line therapy had significantly longer progression-free survival than those who maintained the aromatase-inhibitor combination. (Funded by AstraZeneca; SERENA-6 ClinicalTrials.gov number, NCT04964934.).